Oxygenta Pharmaceutical Limited reported earnings results for the second quarter and six months ended September 30, 2022. For the second quarter, the company reported sales was INR 60.57 million compared to INR 154.86 million a year ago. Revenue was INR 60.57 million compared to INR 154.87 million a year ago. Net loss was INR 23.36 million compared to INR 5.63 million a year ago. Basic loss per share from continuing operations was INR 1.64 compared to INR 0.4 a year ago. Diluted loss per share from continuing operations was INR 1.64 compared to INR 0.4 a year ago.
For the six months, sales was INR 149.5 million compared to INR 375.19 million a year ago. Revenue was INR 149.5 million compared to INR 375.19 million a year ago. Net loss was INR 40.3 million compared to INR 0.894 million a year ago. Basic loss per share from continuing operations was INR 2.84 compared to INR 0.06 a year ago. Diluted loss per share from continuing operations was INR 2.84 compared to INR 0.06 a year ago.